Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
655 studies found for:    "Hypertension, Pulmonary"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Simvatstatin Used to Treat Pulmonary Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: simvastatin
2 Unknown  Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults
Conditions: Chronic Obstructive Pulmonary Disease;   Hypertension, Pulmonary
Intervention: Drug: DHEA Treatment
3 Recruiting Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults
Conditions: Chronic Obstructive Pulmonary Disease;   Hypertension, Pulmonary
Interventions: Drug: DHEA treatment;   Drug: Placebo
4 Recruiting Aerobic Exercise in Patients With Pulmonary Hypertension
Condition: Hypertension, Pulmonary
Interventions: Procedure: Excerise Training;   Procedure: Patient Education (Placebo)
5 Completed
Has Results
Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension
Conditions: Thalassemia;   Hypertension, Pulmonary
Intervention: Drug: Sildenafil
6 Completed Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension
Conditions: Pulmonary Fibrosis;   Hypertension, Pulmonary
Intervention: Drug: Sildenafil (50 mg)
7 Completed Safety and Efficacy of Bosentan in Patients With Diastolic Heart Failure and Secondary Pulmonary Hypertension
Conditions: Heart Failure, Diastolic;   Hypertension, Pulmonary
Interventions: Drug: bosentan;   Drug: placebo
8 Recruiting Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: Iloprost (Ventavis, BAYQ6256)
9 Recruiting Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery
Conditions: Hypertension, Pulmonary;   Ventricular Dysfunction, Left
Intervention: Drug: IK-3001
10 Terminated A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction
Conditions: Hypertension, Pulmonary;   Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (BAY63-2521);   Drug: Placebo
11 Completed Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years
Condition: Hypertension, Pulmonary
Intervention: Drug: Iloprost (Ventavis, BAYQ6256)
12 Completed
Has Results
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
Conditions: Hypertension, Pulmonary;   Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Riociguat (Adempas, BAY63-2521) 1.0 mg;   Drug: Riociguat (Adempas, BAY63-2521) 2.5 mg
13 Active, not recruiting
Has Results
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Conditions: Hypertension, Pulmonary;   Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
14 Completed An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat (Adempas, BAY63-2521)
15 Recruiting Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension Due to Left Ventricular Dysfunction
Conditions: Pre-capillary Pulmonary Hypertension;   Post-capillary Pulmonary Hypertension;   Left Ventricular Dysfunction
Interventions: Drug: Macitentan;   Drug: Placebo
16 Completed Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: Ventavis (Iloprost, BAYQ6256)
17 Active, not recruiting Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)
Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat (Adempas, BAY63-2521)
18 Unknown  The Role of Endothelin in Pulmonary Hypertension
Condition: Pulmonary Hypertension
Intervention: Drug: BQ-123
19 Recruiting Latent Pulmonary Hypertension (PH) in Chronic Thromboembolic Pulmonary Hypertension (CTEPH )After Endarterectomy and Influence of Exercise and Respiratory Therapy
Conditions: Pulmonary Hypertension;   Chronic Thromboembolic Pulmonary Hypertension
Interventions: Behavioral: exercise and respiratory therapy;   Other: sedentary control group
20 Recruiting Zürich Pulmonary Hypertension Outcome Assessment Cohort
Condition: Pulmonary Hypertension Outcome Assessment
Intervention: Other: PH target therapy according to physician

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years